Special Project in Non-Metastatic Castrate Resistant Prostate Cancer

Prostate Cancer Canada (PCC) has offered investigator-initiated Special Project in Non-Metastatic Castrate Resistant Prostate Cancer (NM-CRPC). This request for applications (RFA) solicited proposals from groups interested in combining various real world data sources (i.e. detailed chart review at prostate cancer centres with health administrative databases) to obtain high quality epidemiological data, outcomes and costs among the population of prostate cancer patients in at least two provinces in Canada that together represent greater than 50% of the population.
 
The key objectives were:
  • to obtain prevalence, incidence and survival probability estimates of prostate cancer, stratified by age and year of diagnosis from provincial cancer registries;
  • to identify pathways leading to and factors associated with the target condition (NM-CRPC);
  • to estimate annual incidence and prevalence of NM-CRPC, stratified probability of developing NM-CRPC and transition probabilities that characterize the prognosis from NM-CRPC to metastasis and end-of-life;
  • to estimate health care resource use and costs for health states in the recurrent disease model.
 
Award amount: up to $450,000 over 2 years

 




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Discovery of a promising new medication to block 'master key' of cancer growth

Vancouver, BC – For years, researchers have investigated approaches to prevent cancer-causing cells from multiplying in the body.
More

RFP: Content Development and Delivery of an Accredited Electronic Continuing Medical Education Course for Prostate Cancer Specialists

Prostate Cancer Canada invites applications from service providers interested in the development, promotion and delivery of an accredited electronic Continuing Medical Education course targeting prostate cancer specialists, including urologists.
More

Prostate Cancer Canada announces new President and CEO

Toronto, December 21, 2017 – After five successful years under the leadership and guidance of outgoing President and CEO, Rocco Rossi, Prostate Cancer Canada (PCC) is excited to announce the appointment of a most worthy successor in Peter Coleridge, past national CEO of the Canadian Mental Health Association and current national President and CEO of Big Brothers Big Sisters of Canada.
More


Click here for news archive